Nurix, Inc. announced the appointments of David Lacey, M.D., and Perry Karsen to the company’s board of directors. In addition, Tim Kutzkey, Ph.D., a partner at The Column Group, has been appointed chairman of the board. In conjunction with the new board appointments, Mark Goldsmith, M.D., Ph.D., founding president, CEO and board director of Revolution Medicines and venture partner at Third Rock Ventures, has resigned from the company’s board of directors. Mr. Karsen will represent Third Rock Ventures on the Nurix board. Mr. Karsen served as the CEO of Celgene Cellular Therapeutics from 2013 until his retirement from Celgene at the end of 2015. Following his retirement in 2011, Dr. Lacey has continued to be active in the biopharmaceutical industry. His current activities include advising academic institutions, biotechnology companies and venture capital firms.